Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05045534
Other study ID # TB-840-PRT-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 14, 2021
Est. completion date December 30, 2022

Study information

Verified date July 2023
Source Therasid Bioscience
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TB-840(Agonist of RORα) is a candidate for NASH treatment that activates RORα(Retinoid-related orphan receptor) and its target validation for RORα and potential as a NASH treatment. This study is a dose block-randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. For each dose group, 6 subjects will be randomly assigned to the test group (TB-840) and 2 subjects will be randomly assigned to the control group (placebo). Adverse event (AE) monitoring, physical examination, vital signs, ECG, clinical laboratory test will be done for safety and tolerability assessment, and blood and urine samples will be collected for Pharmacokinetic (PK) assessment.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date December 30, 2022
Est. primary completion date August 29, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy adults aged = 19 and = 45 years at the time of screening visit - BMI of = 18.0 and = 27.0 kg/m2 at the time of screening visit - Clinically confirmed as healthy based on the medical history, physical examination, vital signs, electrocardiography (ECG), and proper laboratory tests (Subjects with values out of the normal range may participate in the study if they are deemed clinically insignificant by the investigator.) - Agree to use medically acceptable methods of contraception by participant, his/her spouse, or partner and not to donate sperm or oocyte from the date of the first dose of the investigational product (IP) until 90 days after the last dose of the IP - Examples of medically acceptable methods of contraception - Females (females who use oral hormonal contraceptives and subcutaneous hormonal contraceptive implants may be excluded from the study) - Use of an intrauterine device with a proven pregnancy failure rate - Use of barrier method with spermicide - Surgical sterilization (salpingectomy/tubal ligation, hysterectomy, etc.) - Males - Use of barrier method with spermicide - Surgical sterilization (vasectomy, vasoligation, etc.) - Voluntarily decided to participate in the study and provided written consent to comply with the protocol Exclusion Criteria: - Current or history of a clinically significant hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, or cardiovascular disease - History of gastrointestinal diseases (e.g., Crohn's disease, ulcer, etc.) or surgery (excluding simple appendectomy or hernia repair) that may affect the absorption of the investigational products - History of clinically significant hypersensitivity to drugs containing RORa agonist or other ingredients of the same class, or other drugs (aspirin and non-steroidal anti-inflammatory drugs, antibiotics, etc.) - History of drug abuse or positive result from urine drug screening of drugs with concerns of drug abuse - Subjects with any of the following results at the time of screening visit: - Systolic blood pressure: < 90 mmHg or > 140 mmHg - Diastolic blood pressure: < 50 mmHg or > 90 mmHg - Heart rate: < 50 bpm or > 100 bpm - AST: > x 1.5 ULN - ALT: > x 1.5 ULN - ALP: > x 1.5 ULN - T.bil: > x 1.5 ULN - ?-GT: > x 1.5 ULN - Serum creatinine: > x 1.5 ULN - Participated in another bioequivalence study or clinical study and have been exposed to an investigational product within 6 months prior to the date of the first dose of this study - Donated whole blood within 2 months or blood components within 1 month, or received blood transfusion within 1 month prior to the date of the first dose of this study - Use of drug-metabolizing enzyme inducer or inhibitor such as barbiturates within 1 month prior to the date of the first dose of this study - Consumption of caffeine- or grapefruit-containing foods or beverages within 3 days prior to the date of the first dose of this study - Use of any prescription drugs or herbal medicines within 1 month, or any over-the-counter (OTC) drugs within 1 week prior to the date of the first dose of this study (Subjects may participate in the study if such use is judged not to significantly affect the assessment of safety and pharmacokinetics by the investigator.) - Excessive intake of caffeine, excessive intake of alcohol, or heavy smoking (caffeine > 5 units/day, alcohol > 21 units/week [1 unit = 10 mL of pure alcohol], smoking > 10 cigarettes/day) - Unable to consume meals provided by the study site - Prior participation in this study - Positive result in serology tests (hepatitis B tests, human immunodeficiency virus [HIV] tests, hepatitis C tests, or syphilis tests [RPR]) - Determined inappropriate for the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Comparison of TB-840 treatment with Placebo
Single dose or Multiple Dose of TB-840 treatment

Locations

Country Name City State
Korea, Republic of Therasid Bioscience Seongnam-si Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
Therasid Bioscience

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 Incidences of treatment-emergent adverse events Up to 10 days from single ascending dose
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 Incidences of treatment-emergent adverse events Up to 14 days from multiple ascending dose
Secondary Maximum concentration of drug in plasma[Cmax] Pharmacokinetic Profile of TB-840 Up to 4 days from single ascending dose
Secondary Maximum concentration of drug in plasma[Cmax] Pharmacokinetic Profile of TB-840 Up to 8 days from multiple ascending dose
Secondary Area under the plasma drug concentration-time curve[AUC] Pharmacokinetic Profile of TB-840 Up to 4 days from single ascending dose
Secondary Area under the plasma drug concentration-time curve[AUC] Pharmacokinetic Profile of TB-840 Up to 8 days from multiple ascending dose
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1